Implications of Cancer Staging Uncertainties in Radiation Therapy Decisions

Introduction . Radiation therapy (RT) for cancer is a critical medical procedure that occurs in a complex environment involving numerous health professionals, hardware, software, and equipment. Uncertainties and potential incidents can lead to inappropriate administration of radiation to patients, with sometimes catastrophic consequences such as premature death or appreciably impaired quality of life. The authors evaluate the impact of incorrectly staging (i.e., estimation of extent of cancer) breast cancer patients and resulting inappropriate treatment decisions. Methods . The authors employ analytic and simulation methods in an influence-diagram framework to estimate the probability of incorrect staging and treatment decisions. As inputs, they use a combination of literature information on the accuracy and precision of pathology and tests as well as expert judgment. Sensitivity and value-of-information analyses are conducted to identify important uncertainties. Results and conclusions . The authors find a small but nontrivial probability that breast cancer patients will be incorrectly staged and thus may be subjected to inappropriate treatment. Results are sensitive to a number of variables, and some routinely used tests for metastasis have very limited information value. This work has implications for the methods used in cancer staging, and the methods are generalizable for quantitative risk assessment of treatment errors.

[1]  A. Vecchione,et al.  Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. , 1999, Anticancer research.

[2]  M. Laberge [Cancer of the breast]. , 1961, Laval medical.

[3]  B Padovani,et al.  Etiologic diagnosis of hepatic lesions in cancer patients. Value of ultrasound and liver function tests. , 1997, Clinical imaging.

[4]  B J McNeil,et al.  Computed tomography, ultrasound, and scintigraphy of the liver in patients with colon or breast carcinoma: a prospective comparison. , 1983, Radiology.

[5]  Louis Anthony Cox,et al.  Risk Analysis Foundations, Models, and Methods , 2001 .

[6]  W. D. Bostick,et al.  Biological markers as an aid in the clinical management of patients with liver metastases , 1982, Journal of surgical oncology.

[7]  A P Forrest,et al.  Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. , 1996, Lancet.

[8]  S. Yasuda,et al.  Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy , 2001, Nuclear medicine communications.

[9]  Ralph L. Keeney,et al.  Value-Focused Thinking: A Path to Creative Decisionmaking , 1992 .

[10]  D. Theodorescu,et al.  Impact of second opinion pathology in the definitive management of patients with bladder carcinoma , 2001, Cancer.

[11]  R C Lee,et al.  221 DEVELOPMENT OF HUMAN EXPOSURE-FACTOR DISTRIBUTIONS USING MAXIMUM-ENTROPY INFERENCE , 1995 .

[12]  G J Rosenbusch,et al.  [Reliability of sonography in diagnosing liver metastases in breast and bronchial cancer. A retrospective comparison of physical examination, laboratory tests and liver scintigraphy]. , 1986, Ultraschall in der Medizin.

[13]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[14]  Gisela del Rocío Estrada-Sánchez,et al.  [Reliability of CA 15-3 in the follow up of female patients with breast carcinoma and bone metastases]. , 2003, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[15]  A. Lluch,et al.  Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis , 2005, Breast Cancer Research and Treatment.

[16]  Gisela del Rocío Estrada Sánchez,et al.  Confiabilidad del CA 15-3 como seguimiento en las pacientes con carcinoma mamario y metástasis óseas , 2003 .

[17]  E T BELL,et al.  The Diseases of the Breast , 1925, Nature.

[18]  R. Sirota,et al.  Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome , 2000, Cancer.

[19]  A. C. Lind,et al.  Prospective peer review in surgical pathology. , 1995, American journal of clinical pathology.

[20]  Norman Wolmark,et al.  Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J Hermans,et al.  Prospective comparative study of ultrasound, CT-scan, scintigraphy and laboratory tests to detect hepatic metastases. , 1991, Journal of nuclear biology and medicine.

[22]  J O Prior,et al.  The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer , 2003, Nuclear medicine communications.

[23]  M. Weinstein,et al.  Clinical Decision Analysis , 1980 .

[24]  W. H. M. Schattevoet,et al.  Die Zuverlässigkeit der Sonographie bei der Diagnostik von Lebermetastasen beim Mamma- und Bronchialkarzinom , 2008 .

[25]  D. Carlow Status report. Canadian association of provincial cancer agencies. , 2000, Chronic diseases in Canada.

[26]  F. J. Davis,et al.  Illustration of Sampling‐Based Methods for Uncertainty and Sensitivity Analysis , 2002, Risk analysis : an official publication of the Society for Risk Analysis.

[27]  A. Ramsay,et al.  The Clinicopathological Meeting: A Means of Auditing Diagnostic Performance , 1993, The American journal of surgical pathology.

[28]  G. Fuller,et al.  Diagnostic discrepancies and their clinical impact in a neuropathology referral practice , 1997, Cancer.

[29]  M Torres,et al.  CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA , 1995, The International journal of biological markers.

[30]  W. Westra,et al.  The impact of second opinion surgical pathology on the practice of head and neck surgery: A decade experience at a large referral hospital , 2002, Head & neck.

[31]  C A Williams,et al.  The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Mcgarrity,et al.  An analysis of imaging studies and liver function tests to detect hepatic neoplasia , 1987, Digestive Diseases and Sciences.

[33]  P. Ferrari,et al.  The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy , 1999, British Journal of Cancer.

[34]  Ross D. Shachter,et al.  Representation and Analysis of Medical Decision Problems with Influence Diagrams , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[35]  Jong-Hyeon Jeong,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002, The New England journal of medicine.

[36]  L. Frati,et al.  Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer , 1995, The International journal of biological markers.

[37]  D. Elder,et al.  Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. , 2002, Archives of dermatology.

[38]  Max Henrion,et al.  Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis , 1990 .

[39]  M. Hou,et al.  Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. , 1999, The Kaohsiung journal of medical sciences.

[40]  Monica Morrow,et al.  Changes in breast cancer therapy because of pathology second opinions , 2002, Annals of Surgical Oncology.

[41]  R. Nakhleh,et al.  Amended reports in surgical pathology and implications for diagnostic error detection and avoidance: a College of American Pathologists Q-probes study of 1,667,547 accessioned cases in 359 laboratories. , 1998, Archives of pathology & laboratory medicine.

[42]  P. Ferrari,et al.  The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer , 2000, British Journal of Cancer.

[43]  David C. Smith,et al.  Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial , 1996, The Lancet.

[44]  Z Kusić,et al.  Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. , 1999, Nuclear medicine communications.

[45]  W. Yasmineh,et al.  Value of alkaline phosphatase, 5'-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liver. , 1977, Clinical chemistry.

[46]  Hans-Jürgen Gallowitsch,et al.  F-18 Fluorodeoxyglucose Positron-Emission Tomography in the Diagnosis of Tumor Recurrence and Metastases in the Follow-Up of Patients With Breast Carcinoma: A Comparison to Conventional Imaging , 2003, Investigative radiology.

[47]  A. Y. Foo,et al.  Measurement of biliary alkaline phosphatase by mini-column chromatography and by electrophoresis and its application to the detection of liver metastases in patients with breast cancer. , 1984, Journal of clinical pathology.

[48]  M. Brandeau,et al.  Operations research and health care : a handbook of methods and applications , 2004 .

[49]  J. Grieve,et al.  Quality Assurance of Histopathologic Diagnosis in the British Army: Role of the Army Histopathology Registry in Completed Case Review , 1986, Journal of the Royal Army Medical Corps.

[50]  J Hermans,et al.  Hepatic metastases: comparative study of diagnostic ultrasound, CT, nuclear scintigraphy and laboratory tests. , 1991, The Netherlands journal of surgery.

[51]  A Pupi,et al.  Staging Breast Cancer - Screening for Occult Metastases , 1985, Tumori.

[52]  E. Imhoff,et al.  Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer , 2004, European Radiology.

[53]  Fiorella Guadagni,et al.  Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer , 2001, Breast Cancer Research and Treatment.

[54]  D. Miller,et al.  Pathology Slide Review in Gynecologic Oncology , 1998, Obstetrics and gynecology.

[55]  M Untch,et al.  Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases. , 1998, Anticancer research.

[56]  Averill M. Law,et al.  Simulation Modeling and Analysis , 1982 .

[57]  K. Holli,et al.  Role of Chest X-ray in Diagnosis of the First Breast Cancer Relapse: A Randomized Trial , 2003, Breast Cancer Research and Treatment.

[58]  M. Góralczyk,et al.  [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases]. , 2001, Przeglad lekarski.

[59]  Dino Amadori,et al.  Staging of Breast Cancer: New Recommended Standard Procedure , 2002, Breast Cancer Research and Treatment.

[60]  D K Owens,et al.  Use of Influence Diagrams to Structure Medical Decisions , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[61]  F. Guadagni,et al.  A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.